Anthropic Buys Coefficient Bio in $400 Million Deal
The acquisition gives Anthropic a small team of biotech researchers and engineers as it pushes further into life sciences.
Topics
News
- Tech Firms Must Reskill Workers Before Layoffs, IT Body Says
- ElevenLabs Launches AI Music App to Challenge Suno, Udio
- Anthropic Buys Coefficient Bio in $400 Million Deal
- Bengaluru GenAI Firm NeuroPixel Shuts Down, Citing Surge in Big Tech Models
- Sarvam Seeks to Raise $350 Million at $1.55 Billion Valuation
- The Five Skills LinkedIn Says Will Keep Humans Ahead of AI
Anthropic has acquired stealth biotech startup Coefficient Bio in a stock deal valued at about $400 million, The Information reported, citing people aware of the developments.
The deal has closed, TechCrunch reported, though Anthropic has not publicly confirmed the details.
The acquisition deepens Anthropic’s push into healthcare and life sciences, an area it formally entered in October 2025 with the launch of Claude for Life Sciences.
At the time, the company said it was building tools to help researchers work across tasks including literature reviews, hypothesis generation and bioinformatics workflows, with connectors to platforms such as Benchling, BioRender and PubMed.
Anthropic widened that effort in January, saying it was expanding Claude’s capabilities for scientists and clinicians and adding support for use cases ranging from clinical trial management to regulatory operations.
Coefficient Bio, founded eight months ago by Samuel Stanton and Nathan C. Frey, had been working on applying AI to improve efficiency in drug discovery and broader biological research.
Both founders previously worked in computational drug discovery at Genentech’s Prescient Design team.
The startup has built a compact team of around 10 researchers and engineers, all of whom are expected to join Anthropic as part of its expanding health and life sciences division.
The deal suggests Anthropic wants more than partnerships and product integrations as it tries to build a position in scientific research.
Buying Coefficient gives it a specialized team at a time when leading AI companies are pushing beyond general-purpose models and into high-value fields such as biology and healthcare.
The deal aligns with growing optimism around AI’s role in transforming biotech.
In a recent conversation with Nikhil Kamath, Anthropic CEO Dario Amodei said he expects a wave of innovation driven by AI in the sector.
“Biotech is about to have a renaissance… ultimately driven by AI,” he noted, pointing to areas such as peptide-based therapies and cell-based treatments like CAR-T as ripe for acceleration through AI-led design.
Anthropic has also been actively shaping industry dialogue. At its recent event, The Briefing: Healthcare & Life Sciences, the company brought together leaders to discuss how AI is transforming the sector.
Speaking at the event, Amodei highlighted the compounding impact of AI on research: “If we speed up basic research, everything comes downstream from that: more discoveries in fundamental biology, more drug candidates, drugs with larger effect sizes, better care for patients.”
